Standard BioTools 3Q 2026: Revenue $19.4M, Net income $13.5M, EPS $0.03— 10-Q Summary
Moins d'1 minute de lecture
Standard BioTools reported third-quarter 2026 revenue of $19.4M, down 0.9% from $19.6M a year earlier. Net income was $13.5M, compared with a $34.7M net loss in the prior-year quarter, while diluted EPS was $0.03 versus a loss of $0.09; current-quarter results included $28.5M of income from discontinued operations.
Financial Highlights
- Revenue was $19.4M, compared with $19.6M in the prior-year quarter; YoY change (0.9%).
- Net income was $13.5M, compared with a net loss of $34.7M in the prior-year quarter.
- Diluted EPS was $0.03, compared with a loss of $0.09 in the prior-year quarter.
Business Highlights
- Third-quarter instrument sales rose 18% year over year, offset by lower consumables and service revenue. For the first nine months, consumables revenue grew 5%, while instruments declined 8% and services and other revenue fell 5%.
- The SomaScan sale closed in January. The company plans to sell its mass cytometry business to Element Biosystems and its microfluidics business to ARCHIMED.
- The registration statement for the Treeline merger became effective October 21, 2026. A stockholder vote is scheduled for November 19, with closing expected in the fourth quarter.
- Management said workforce reductions and the consolidation of research and development in Singapore lowered costs, and that available liquidity is expected to support operations for at least 12 months.
Original SEC Filing: STANDARD BIOTOOLS INC. [ LAB ] - 10-Q - Nov. 03, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.